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Abstract
Background: Mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) are frequent
in low-grade gliomas and secondary glioblastomas (sGBM). Because they yield the same oncometabolite,
D-2-hydroxyglutarate, they are often treated as equivalent and pooled. The objective of this study was to provide
insight into the differences between IDH1 and IDH2 mutant gliomas.
Methods: To investigate the different clinical and molecular characterization between IDH1 mutant and IDH2
mutant gliomas, we studied 811 patients with IDH1 mutations, IDH2 mutations and IDH1/2 wild-type. In addition,
whole-transcriptome sequencing and DNA methylation data were used to assess the distribution of genetic
changes in IDH1 and IDH2 mutant gliomas in a Chinese population-based cohort.
Results: Among 811 gliomas in our cohort, 448 cases (55.2 %) harbored an IDH1 mutation, 18 cases (2.2 %)
harbored an IDH2 mutation and 345 cases (42.6 %) harbored an IDH1/2 wild-type. We found that IDH1 and IDH2
are mutually exclusive in gliomas, and IDH2 mutations are mutually exclusive with PTEN, P53 and ATRX mutations.
Patients with IDH2 mutations had a higher frequency of 1p/19q co-deletion (p < 0.05) than IDH1 mutant patients.
In addition, a Gene Set Enrichment Analysis (GSEA) showed that IDH2 mutant gliomas were associated with the
oxidative phosphorylation gene set, and the four most representative biological processes for genes commonly
altered by hypermethylation in IDH2 mutant gliomas were the regulation of cell proliferation, cell motion, cell
migration and response to hypoxia. Patients with IDH2 mutant gliomas exhibited longer Overall survival (OS) (p < 0.05)
and longer Progression-free survival (PFS) (p < 0.05) than patients with IDH1/2 wild-type gliomas. However, their OS and
PFS did not differ from that of IDH1 mutant patients.
Conclusions: Our study revealed an intrinsic distinction between IDH1 and IDH2 mutant gliomas, and these mutations
should be considered separately because their differences could have implications for the diagnosis and treatment of
IDH1/2 mutant gliomas.
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Background
Isocitrate dehydrogenase (IDH) enzymes encode the
NADP+-dependent isocitrate dehydrogenase, which cata-
lyzes the oxidative decarboxylation of isocitrate to form
an α-ketoglutarate (α-KG). IDH1 and IDH2 proteins
share a high degree of sequence similarity (70 % in
humans) and are encoded by distinct genes (IDH1, 2q33
and IDH2, 15q26). Mutations in IDH1 and IDH2, which
represent the most frequently mutated metabolic genes in
human cancer, are implicated to be mutated in more than
50–80 % of low-grade gliomas and secondary glioblast-
omas (sGBM), 10 % of intrahepatic cholangiocarcinoma,
20 % of acute myeloid leukemia (AML), 56 % of chondro-
sarcomas, and over 10 % of melanoma cases [1–5].
Although IDH1 and IDH2 are highly similar and catalyze
identical reactions, IDH1 is localized in the cytosol and
IDH2 is found in the mitochondrial matrix. In addition,
the spectrum of cancers and their subtypes are differ-
ent. For example, IDH1 mutations are predominant in
gliomas, chondrosarcoma, and cholangiocarcinoma,
whereas IDH1 mutations and IDH2 mutations are
equally common in AML. Despite their different
physiological characteristics, most genomic studies of
the molecular landscapes in human cancer have fre-
quently combined IDH1 mutations and IDH2 muta-
tions as a single functional group.
Glioma, the most common primary brain tumor, is
classified as grade I to IV based on histopathological and
clinical criteria established by the 2007 World Health
Organization (WHO) [6]. WHO grade I gliomas are often
curable by surgical resection, whereas WHO grade II or
III gliomas are invasive and have a poor prognosis. WHO
grade IV tumors (glioblastomas), the most invasive tu-
mors, feature a median survival of only 16 months, even
after aggressive treatment consisting of surgery, radiation
therapy, and chemotherapy [7]. In 2008, the genes encod-
ing IDH1 were found to be mutated in low-grade gliomas
and a subset of sGBM [8]. In subsequent studies, IDH1
mutations were reported to occur in 70–80 % of WHO
grade II or III astrocytomas, oligodendrogliomas, and oli-
goastrocytomas, whereas a small group (3–5 %) were
found to harbor IDH2 mutations [1]. This pattern con-
trasts that observed in AML, which features similar rates
of IDH1 (6.6 %) and IDH2 mutations (10.8 %) [9]. More-
over, mutations of IDH1 and IDH2 are mutually exclusive
in gliomas, and biochemical investigations showed that
IDH1 and IDH2 mutations differ in D-2-hydroxyglutarate
(D-2HG) production in gliomas [10]. This difference sug-
gests that IDH1 and IDH2 mutations may impact different
cellular pathways and exert different tumorigenic effects.
To investigate the different clinical and molecular
characterization between IDH1 mutant and IDH2 mutant
gliomas, we studied a cohort of 811 patients consisting 448
IDH1 mutant, 18 IDH2 mutant and 345 IDH1/2 wild-type
gliomas. We performed whole-transcriptome sequencing
and DNA methylation analyses of the samples obtained
from patients. We compared the mutational landscapes of
IDH1 and IDH2 mutant gliomas, their clinical associations,
overall survival, and progression-free survival. Our aim was
to provide insight into the differences between IDH1 and
IDH2 mutant gliomas.
Methods
Patients and tumor samples
Glioma samples were obtained from 811 patients with
gliomas, including 448 IDH1 mutant, 18 IDH2 mutant
and 345 IDH1/2 wild-type gliomas, which were composed
of 577 low grade (II + III) gliomas, including 193 diffuse
astrocytoma, 39 anaplastic astrocytomas, 49 low-grade
oligodendrogliomas, 27 anaplastic oligodendrogliomas, 186
oligoastrocytomas, 83 anaplastic oligoastrocyotmas and 234
glioblastomas. These patients underwent surgery and were
followed-up at Beijing Tiantan hosipital from 2004 to 2014.
Table 1 The summary of the materials analysed in this study
Pathological diagnosis WHO grade n = 811 IDH1 mutation No. (%) IDH2 mutation No. (%) IDH mutation total No. (%)
Diffuse astrocytoma II 193 138 (71.5) 2 (1.0) 140 (72.5)
Anaplastic astrocytoma III 39 14 (35.9) 0 (0) 14 (35.9)
Oligodendroglioma II 49 38 (77.6) 3 (6.1) 41 (83.7)
Anaplastic oligodendroglioma III 27 19 (70.4) 1 (3.7) 20 (74.1)
Oligoastrocytoma II 186 147 (79.0) 9 (4.8) 156 (83.8)
Anaplastic oligoastrocytoma III 83 47 (56.6) 1 (1.2) 48 (57.8)
Subtotal (grades II and III) 577 403 (69.8) 16 (2.8) 419 (72.6)
Primary GBM IV 205 29 (14.1) 1 (0.5) 30 (14.6)
Secondary GBM IV 29 16 (55.2) 1 (3.4) 17 (58.6)
Subtotal (Glioblastoma) IV 234 45 (19.2) 2 (0.9) 47 (20.1)
Total 811 448 (55.2) 18 (2.2) 466 (57.4)
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Clinicopathologic data, including gender, age, pathologic
diagnosis and the results of molecular analysis were ob-
tained. When the cases were classified as secondary GBMs
based on biopsy-proven preexisting low-grade gliomas, 29
cases (12.4 %) were secondary GBM and the remainder
were primary GBM (205 cases, 87.6 %).
Whole transcriptome sequencing of 161 gliomas and
DNA methylation profile of 44 glioma samples, were
obtained from Chinese Glioma Genome Atlas (CGGA)
database (http://www.cgga.org.cn) [11–13]. All these
samples were histologically graded according to 2007
WHO classification of tumours of the nervous systems
[6]. Written informed consent was obtained from all do-
nors. Clinical investigations were performed after ap-
proval by the local research ethics committee and in
accordance with the ethical principles.
IDH mutation
Genomic DNA was isolated from frozen tissues with a
QIAamp DNA Mini Kit (Qiagen) according to the manu-
facturer’s protocol. The DNA concentration and quality
were evaluated with a Nano-Drop ND-1000 spectropho-
tometer (NanoDrop Technologies, Houston, TX). The py-
rosequencing of IDH1/2 mutations was supported by
Gene-tech (Shanghai, China) and performed on a Pyro-
Mark Q96 ID System (Qiagen, Valencia, Calif). The primers
5′-GCTTGTGAGTGGATGGGTAAAAC-3′, 5′-Biotin-TT
GCCAACATGACTTACTTGATC-3′, for IDH1 and 5′-AT
CCTGGGGGGGACTGTCTT-3′, 5′-Biotin-CTCTCCAC
CCTGGCCTACCT-3′ for IDH2 were used for PCR ampli-
fication, and the primers 5′-TGGATGGGTAAAACCT-3′
for IDH1 and 5′-AGCCCATCACCATTG-3′ for IDH2
were used for pyrosequencing [13].
Gene set enrichment analysis
To identify the gene sets related to particular biological
processes present in IDH-mutant patients, gene expres-
sion profiling and a gene set enrichment analysis (GSEA)
were performed as described previously [14].
Statistical analysis
Survival distributions were estimated with a Kaplan-Meier
survival analysis, and the log-rank test was used to assess
the significance of differences between stratified survival
groups using the GraphPad Prism 5.0 statistical software.
The differences among patients in baseline clinical and
molecular features according to IDH1 and IDH2 muta-
tional status were tested using the Fisher’s exact and
Wilcoxon rank sum tests for categoric and continuous
variables, respectively. Gens that were differently meth-
ylated between IDH2 mutant and IDH1 mutant tumors
were obtained using the standard two-sampled t-test
with unequal variance and sample size. To adjust for
multiple comparisons, we applied the Benjamini-Hochberg
method to control the False Discovery Rate at 5 %. We fur-
ther filtered the list of significant genes by retaining those
which exhibited at least 1.5-fold difference in gene ex-
pression between IDH2 mutant and IDH1 mutant in
our final comparisons. Student’s t-test was performed
using SPSS 16.0. A two-sided p value < 0.05 was considered
significant.
Results
Clinical and molecular characterization of IDH2 mutations
Among a total of 811 gliomas, IDH2 mutations were
identified in 18 cases (2.2 %) (Table 1). IDH2 mutations
were found in 0.5 % of pGBM (1/215), 3.4 % of sGBM
(1/29) and 2.8 % (16/577) of low grade gliomas, while
Fig. 1 Overview of clinical and molecular characterization of the cohort (n = 811). Each column represents a patient
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Table 2 Clinical characteristics according to IDH mutational status in gliomas
Clinical characteristic N = 811 IDH1-Mutated IDH2-Mutated IDH1/IDH2-Wild-type P (IDH1-Mutated VS
IDH1/IDH2- Wild-type)




No. (%) No. (%) No. (%)
Age, years <45 423 285 (67.4) 13 (3.1) 125 (29.5) <0.001 <0.05 0.456
≥45 388 163 (42.0) 5 (1.3) 220 (56.7)
Median age, years 39.1 37.3 45.0 <0.001 <0.05 0.456
Range 17.0–66.0 26.0–56.0 9.0–81.0
Gender Male 495 265 (53.5) 11 (2.2) 219 (44.2) 0.113 0.801 0.824
Female 316 186 (58.9) 7 (2.2) 123 (38.9)
WHO Grade II + III 577 403 (69.8) 16 (2.8) 158 (27.4) <0.001 <0.001 0.883
IV 234 45 (19.2) 2 (0.9) 187 (79.9)
KPS score <80 74 26 (35.1) 2 (2.7) 46 (62.2) <0.001 0.376 0.514
≥80 253 173 (68.4) 7 (2.8) 73 (28.8)
NA 483 248 9 226
Histologic type Oligodendroglioma 76 57 (75.0) 4 (5.3) 15 (19.7) <0.001 <0.001 0.218
Oligoastrocytoma 269 194 (72.1) 10 (3.7) 65 (24.2)
Astrocytoma 437 181 (41.4) 3 (0.7) 253 (57.9)
sGBM 29 16 (55.2) 1 (3.4) 12 (41.4)
Laterality Left 380 211 (55.5) 9 (2.4) 160 (42.1) <0.05 0.891 0.985
Right 366 203 (55.5) 8 (2.2) 155 (42.3)
Midline 53 33 (62.3) 1 (1.9) 19 (35.8)














IDH1 mutations are found in 14.1 % (29/205) of pGBM,
55.2 % (16/29) of sGBM and 69.8 % (403/577) of low
grade gliomas. Combined IDH1 and IDH2 mutations
were found in 14.6 % (30/205) of pGBM, 58.6 % (17/29)
of sGBM and 72.6 % (419/577) of low grade gliomas.
As shown in Fig. 1 and Table 2, patients with muta-
tions in IDH2 did not differ from IDH1-mutant patients
in terms of age, gender, WHO grade, KPS, histologic
type and laterality (Table 2). To characterize the mo-
lecular features of IDH2 mutant gliomas, we analyzed
associations between IDH2 mutations and other muta-
tional events. Patients with IDH2 mutations had a
higher frequency of 1p/19q co-deletion (p < 0.05) and a
lower frequency of P53 mutation (p < 0.05) than IDH1
mutant patients (Table 3). Strikingly, the presence of
IDH2 mutations and PTEN mutations, P53 mutation
and ATRX mutation did not correlate (Fig. 1 and
Table 3).
Gene set enrichment analysis for IDH2 mutant patients
To gain biologic insight into the potentially significance of
IDH2mutations, we compared the whole-transcriptome se-
quencing expression profiles of 5 IDH2 mutant patients
with 109 IDH1 mutant patients and 47 IDH1/2 wild-type
patients. First, we used a Gene Set Enrichment Analysis
(GSEA) to compare the global gene expression profiles of
the IDH2 mutant and IDH1 mutant gliomas. The result
showed that the oxidative phosphorylation gene set was up-
regulated (FDR q-value = 0; Fig. 2a/c). We then compared
the whole-transcriptome sequencing expression profiles of
the IDH2 mutant and IDH1/2 wild-type gliomas (Fig. 2b).
The results showed that the oxidative phosphorylation gene
set (FDR q-value < 0.001; Fig. 2d) and hedgehog signaling
set were upregulated (FDR q-value < 0.05; Fig. 2e).
IDH2 mutant gliomas exhibit DNA methylation profiles
distinct from those of IDH1 mutant gliomas
Given the DNA methylation profiles of 3 IDH2 mutant
gliomas and 41 IDH1 mutant gliomas, we used stand-
ard t-tests to identify differentially methylated regions.
The methylation patterns of genes that correlated with
IDH2 mutant gliomas are shown in Fig. 3a using a one-
dimensional hierarchical clustering analysis. The four
most representative biological processes for genes com-
monly altered by hypermethylation were the regulation of
cell proliferation, cell motion, cell migration and response
to hypoxia (Fig. 3b). According to the hypomethylated
genes, the three most representative biological processes
were ion transport, cell-cell signaling, and cation transport
(Fig. 3b).
Associations of IDH2 mutations with clinical outcome
In our cohort, the presence of an IDH2 mutation was
associated with a longer overall survival (p < 0.05) and
longer progression-free survival (p < 0.05) (Fig. 4a/b)
than the presence of the IDH1/2 wild-type gene.
However, when considering all patients with IDH2
mutations, the overall survival and time to recurrence
did not differ from those of IDH1 mutant patients
(Fig. 4a/b). This result illustrates that the effects of
IDH2 mutation and IDH1 mutation on clinical prog-
nosis were similar.
Discussion
Mutations in the IDH1 and IDH2 genes have been
found in patients with gliomas and were initially identi-
fied in low-grade gliomas and secondary glioblastomas
[1]. Strikingly, mutations in IDH1 and IDH2 are mutually
exclusive in gliomas. Although the genetic and epigenetic
landscapes of IDH1mutation gliomas have been extensively
Table 3 Molecular characteristics according to IDH mutation in glioma






PTEN Mutation 6 0 43 <0.001 0.098 0.605
Wild-type 314 14 218
NA 128 4 84
1p/19q Co-deletion Absent 341 9 307 <0.001 <0.001 <0.05
Present 106 9 34
NA 1 0 1
P53 Mutation 215 0 232 <0.001 0.154 <0.05
Wild-type 115 14 34
NA 118 4 79
ATRX Mutation 13 0 15 0.084 0.638 0.728
Wild-type 107 5 102
NA 328 13 228
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studied, whether IDH2 mutation gliomas have unique
genetic and epigenetic characteristics that can be used
as targets for future intervention is unknown. In this report,
we compared the clinical and molecular characteristics of
glioma patients harboring IDH1 and IDH2 mutations.
Like mutations in IDH1, mutations in IDH2 affect a
conserved arginine residue (R172) in the substrate-binding
site of the IDH2 enzyme. In our cohort, the presence of an
IDH2 mutation did not correlate with the presence of
PTEN, P53, and ATRX mutations, but a highly significant
positive correlation was observed with the presence of a
1p/19q co-deletion: 44.4 % of IDH2 mutation patients har-
bored a 1p/19q co-deletion. In malignant glioma, IDH1
mutations are ubiquitous in tumor cells, and IDH1 muta-
tions precede secondary and tertiary lesions, suggesting
that IDH1 mutations are an early causative event in the
Fig. 2 Gene Set Enrichment Analysis (GSEA) of overexpressed genes in glioma harboring IDH2 mutations. Each row represents a gene, and each column
indicates a glioma with an IDH2 mutation, IDH1 mutation or IDH1/2 wild-type. Red indicates upregulated genes, and blue indicates downregulated genes.
a Expression levels of genes annotated in IDH2 mutant gliomas compared to IDH1 mutant gliomas. b Expression levels of genes annotated in IDH2 mutant
gliomas compared to IDH1/2 wild-type gliomas. c one representative plot of GSEA from a. d-e two representative plots of GSEA from (b)
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Fig. 3 Clustering analysis of DNA methylation in IDH2 mutant gliomas. a The pattern of DNA methylation was associated with IDH2 mutant gliomas
using a one-dimensional hierarchical clustering analysis. b Functional enrichment analysis of associated genes, indicating the functional roles of gene
sets in different subgroups. Enrichment results for biological processes were obtained from the GO database. The orders of biological processes listed
in the histogram are based on the number of targets annotated in the biological process (BP)
Fig. 4 The Kaplan–Meier estimates for Overall survival (OS) (a) and Progression-free survival (PFS) (b) indicates that IDH2 mutant gliomas associated
with longer overall survival (p = 0.011) and longer progression-free survival (p = 0.011) than IDH1/2 wild-type gliomas. However, the OS and PFS did not
significantly differ between IDH1 mutant and IDH2 mutant gliomas
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genesis of gliomas [15–17]. A pathology study of multiple
biopsies from the same patient found that IDH1 muta-
tions occurred before the acquisition of P53 mutations
and 1p/19q loss of heterozygosity (LOH) [16], suggesting
that IDH1 mutations may result in cellular stress that
leads to the mutation of P53 and 1p/19q loss. However,
IDH2 mutations and PTEN, P53 and ATRX mutations
were mutually exclusive, suggesting that the microenvir-
onment of IDH2 mutations may not create cellular stress
that leads to the other mutations, which needs further re-
search to fully elucidate.
Tumor cells often take up nutrients in excess of their
bioenergetic needs and shunt metabolites into pathways
that support tumor progression [18–20]. During cell pro-
liferation, tumor cells depend on aerobic glycolysis to
meet their bioenergy needs and generate intermediates for
macromolecule biosynthesis. One study demonstrated
that glioma cells harboring mutant IDH1 may maintain
cell proliferation via the glutamate metabolism pathway
[21]. In our study, GSEA was performed for IDH2 and
IDH1 mutations, yielding enriched gene sets related to
oxidative phosphorylation, which is critical to tricarboxylic
acid (TCA) cycle, in the IDH2 mutation subset. This find-
ing corroborates that of a previous study [22, 23]. IDH2 is
localized in the mitochondria and participates in the TCA
to produce energy, whereas IDH1 is localized in the cyto-
plasm and peroxisomes [24]. Consequently, does energy
production in IDH2-mutated gliomas favor oxidative
phosphorylation over aerobic glycolysis? These interesting
findings should be verified in more cases before accepting
them as general characteristics of IDH2-mutated gliomas.
Future work should focus on the potential of therapeutic-
ally targeting compensatory metabolic pathways in IDH2-
mutant gliomas.
Conclusion
In conclusion, our results describe the clinical and bio-
logical characteristics of IDH1 and IDH2 mutations in gli-
omas. Understanding the underlying biology of the
differences in outcome observed for IDH1 and IDH2 mu-
tant gliomas will be important for future studies and may
lead to the development of novel approaches to therapy.
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